Literature DB >> 18248553

The effect of neoadjuvant chemotherapy on histologic grade, hormone receptor status, and HER2/neu status in breast carcinoma.

Amy L Adams1, Isam Eltoum, Helen Krontiras, Wenquan Wang, David C Chhieng.   

Abstract

The use of neoadjuvant chemotherapy prior to surgical resection for breast cancer is no longer restricted to patients with locally advanced disease. As preoperative treatment becomes more common, the question arises whether or not such therapy changes important tumor characteristics. The objective of our study is to compare histological grade, hormone receptor status, and HER2/neu expression pre- and post-therapy patients receiving preoperative neo-adjuvant chemotherapy. Forty patients status post-neoadjuvant treatment who had available archived pathologic material pre- and post-therapy were identified. Glass slides were reviewed retrospectively, and tumor grade, hormone receptor status, and HER2/neu expression were compared between the pre- and post-therapy specimens. No significant differences were noted between the pre- and post-specimens for two of the three parameters comprising the modified Bloom-Richardson grade, including degree of tubule formation (p = 0.062) and nuclear pleomorphism (p = 0.086). For mitotic activity, a decrease in score was observed between pre- and post-therapy specimens which was statistically significant (p = 0.021). However, there was no significant difference in the overall modified Bloom-Richardson grade (p = 0.118). Information was available regarding hormone receptor and HER2/neu status in 26 patients (65%). There was no significant difference between pre- and post-treatment specimens for hormone receptor status. However, there were more patients with HER2/neu overexpression after receiving neoadjuvant therapy (p = 0.027). Neoadjuvant therapy resulted in a significant decrease in mitotic count and an increase in the proportion of patients with HER2/neu overexpression. No significant changes were noted for the degree of tubule formation, nuclear pleomorphism, overall Bloom-Richardson score, and hormone receptor status. However, small sample size may be a limitation of these results.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18248553     DOI: 10.1111/j.1524-4741.2007.00544.x

Source DB:  PubMed          Journal:  Breast J        ISSN: 1075-122X            Impact factor:   2.431


  16 in total

1.  Two cases of matrix-producing carcinoma showing chondromyxoid matrix in cytological specimens.

Authors:  Shogo Tajima; Kenji Koda
Journal:  Int J Clin Exp Med       Date:  2015-07-15

2.  Evaluation of biomarker changes after administration of various neoadjuvant chemotherapies in breast cancer.

Authors:  Guangchao Jin; Yu Han; Cun Liu; Liansheng Chen; Butong Ding; Shijin Xuan; Xianqiang Liu; Guohui Ma; Jun Gao; Xingsong Tian
Journal:  Int J Clin Exp Pathol       Date:  2015-01-01

Review 3.  Applying the New Guidelines of HER2 Testing in Breast Cancer.

Authors:  Huina Zhang; Ioana Moisini; Rana M Ajabnoor; Bradley M Turner; David G Hicks
Journal:  Curr Oncol Rep       Date:  2020-04-29       Impact factor: 5.075

4.  The effect of prolonged cold ischemia time on estrogen receptor immunohistochemistry in breast cancer.

Authors:  Xiaoxian Li; Michael T Deavers; Ming Guo; Ping Liu; Yun Gong; Constance T Albarracin; Lavinia P Middleton; Lei Huo
Journal:  Mod Pathol       Date:  2012-08-17       Impact factor: 7.842

5.  A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China.

Authors:  Peng Xing; Jiguang Li; Feng Jin
Journal:  Med Oncol       Date:  2009-09-23       Impact factor: 3.064

6.  Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy.

Authors:  Hyeon-Man Baek; Jeon-Hor Chen; Ke Nie; Hon J Yu; Shadfar Bahri; Rita S Mehta; Orhan Nalcioglu; Min-Ying Su
Journal:  Radiology       Date:  2009-03-10       Impact factor: 11.105

7.  Estrogen receptor (ER), progesterone receptor (PR), and HER2 expression pre- and post- neoadjuvant chemotherapy in primary breast carcinoma: a single institutional experience.

Authors:  Mary Diane Kinsella; Aziza Nassar; Momin T Siddiqui; Cynthia Cohen
Journal:  Int J Clin Exp Pathol       Date:  2012-07-29

8.  The increasing importance of histologic grading in tailoring adjuvant systemic therapy in 30,843 breast cancer patients.

Authors:  C van Dooijeweert; I O Baas; I A G Deckers; S Siesling; P J van Diest; E van der Wall
Journal:  Breast Cancer Res Treat       Date:  2021-01-30       Impact factor: 4.872

9.  Prognostic value of receptor conversion after neoadjuvant chemotherapy in breast cancer patients: a prospective observational study.

Authors:  Xi Jin; Yi-Zhou Jiang; Sheng Chen; Ke-Da Yu; Zhi-Ming Shao; Gen-Hong Di
Journal:  Oncotarget       Date:  2015-04-20

10.  Change in the hormone receptor status following administration of neoadjuvant chemotherapy and its impact on the long-term outcome in patients with primary breast cancer.

Authors:  T Hirata; C Shimizu; K Yonemori; A Hirakawa; T Kouno; K Tamura; M Ando; N Katsumata; Y Fujiwara
Journal:  Br J Cancer       Date:  2009-10-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.